zinostatin and Carcinoma--Small-Cell

Eighty-two patients with small cell lung carcinoma refractory to standard chemotherapy were entered in this phase II randomized study of PALA, amsacrine, teniposide, and zinostatin. Of the 66 evaluable patients, one partial response occurred among 17 patients treated with teniposide and no responses occurred with the other drugs. Two patients each treated with amsacrine and teniposide experienced life-threatening hematologic toxic effects and one patient treated with zinostatin died of thrombocytopenic pulmonary hemorrhage. The overall median patient survival was 9.6 weeks. Weight loss greater than or equal to 5% prior to therapy, extensive disease, and a nonambulatory status were associated with poor survival.

Topics: Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Aspartic Acid; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Drug Evaluation; Humans; Lung Neoplasms; Phosphonoacetic Acid; Random Allocation; Teniposide; Zinostatin

Eighty-nine patients with advanced non-small cell bronchogenic carcinoma were treated with either m-AMSA 120 mg/m2 intravenously every 3 weeks or neocarzinostatin 2.0 mg/m2 intravenously daily X 5 every 4 weeks. There were no responses in 40 evaluable patients who received m-AMSA and three partial responses (7.5%) in 40 patients who received neocarzinostatin. Two patients receiving m-AMSA had drug-related deaths. For m-AMSA the major toxicities were hematologic, while for neocarzinostatin the major toxicities were hematologic, gastrointestinal, and fever. We conclude that m-AMSA is inactive while neocarzinostatin has minimal activity in non-small cell bronchogenic carcinoma.

Topics: Aged; Aminoacridines; Amsacrine; Antibiotics, Antineoplastic; Antineoplastic Agents; Carcinoma, Bronchogenic; Carcinoma, Small Cell; Drug Administration Schedule; Drug Evaluation; Humans; Lung Neoplasms; Random Allocation; Zinostatin